What is mPharma?
Founded in 2013 and headquartered in Ghana, mPharma is revolutionizing healthcare access in Africa by establishing a robust network of community pharmacies. These pharmacies function as comprehensive healthcare hubs, offering a wide array of services including medical consultations, diagnostic testing, and telehealth. By integrating these services, mPharma aims to enhance both the accessibility and affordability of quality medications and healthcare for millions across the continent. The company's strategic approach positions it as a primary healthcare provider, addressing critical gaps in the existing health infrastructure.
How much funding has mPharma raised?
mPharma has raised a total of $68.3M across 5 funding rounds:
Series A
$6.6M
Series B
$9.7M
Series C
$17M
Debt
$5M
Series D
$30M
Series A (2017): $6.6M with participation from Social Capital, Golden Palm Investments, and 4DX Ventures
Series B (2019): $9.7M led by Cem Garih, Novastar Ventures, and Unbound
Series C (2020): $17M supported by CDC Group Plc
Debt (2022): $5M featuring Citi
Series D (2022): $30M backed by Unbound, Lux Capital, and JAM Fund
Key Investors in mPharma
Citi
Citi, a multinational financial services corporation founded in 1812, provides banking services and financial loans, indicating a role in debt financing for mPharma's operations.
Lux Capital
Lux Capital is a venture capital firm specializing in early-stage and growth-stage companies at the intersection of science and technology, suggesting a focus on mPharma's innovative health tech solutions.
Novastar Ventures
Novastar Ventures is an investment manager focused on fueling entrepreneurial revolutions in Africa, partnering with initiatives that benefit people and the planet, aligning with mPharma's mission to improve healthcare access.
What's next for mPharma?
With the recent major enterprise-level funding, mPharma is poised for accelerated growth and expansion. The strategic investment signals strong confidence from backers in the company's model and its potential to scale its impact. This capital will likely be deployed to further develop its pharmacy network, enhance its technological infrastructure for telehealth and diagnostics, and potentially expand into new African markets. The company's trajectory suggests a continued focus on solidifying its position as a leading pan-African healthcare provider, driving innovation in pharmaceutical access and integrated health services.
See full mPharma company page
